✦ LIBER ✦

Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance

✍ Scribed by Sarah A. Andres; Angelena B. Edwards; James L. Wittliff

Book ID: 112120509
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 835 KB
Volume: 26
Category: Article
ISSN: 0887-8013
DOI: 10.1002/jcla.21488

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical relevance of urokinase-type pla

Clinical relevance of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in oral squamous cell carcinoma (OSCC)

✍ H.-F. Zeilhofer; K.P. Bock; P. Dettmar; B. Hundsdorfer; K. Ulm; R. Sader; H.-H. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Prognostic significance of urokinase pla

Prognostic significance of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer

✍ D Vrbanec; S Jelisavac-Cosic; J Jakic-Razumovic; E Mustac; I Kuzmic-Prusac 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 331 KB

Tissue extraction procedures for investi

Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas

✍ F. Descotes; G. Ville; J.Y. Bobin; Y. Barbier; S. Saez 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 982 KB

Clinical Relevance of Urokinase-Type Pla

Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

✍ Coşkun Tecimer; David L. Doering; L.Jane Goldsmith; John S. Meyer; Gazi Abdulhay 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Agonist activity of antiestrogen-recepto

Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells

✍ Anait S Levenson; Kristen M Svoboda; Hau C Kwaan; V.Craig Jordan 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Expression of urokinase-type plasminogen

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

✍ Maria E. L. van der Burg; Sonja C. Henzen-Logmans; Els M. J. J. Berns; Wim L. J. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 620 KB

Elevated levels of expression of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 have shown to be related to poor prognosis in a variety of cancer types. In the present study, cytosolic levels of uPA and PAI-1 were determined with enzyme-linked immunosorbent assays in cytosols